Armin Ghobadi, MD, Discusses Trials Needed to Build on Blinatumomab Pilot Study Data

News
Video

Ghobadi detailed the next steps needed to build on the results of a study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

In an interview with CancerNetwork®, Armin Ghobadi, MD, of the Washington University School of Medicine in St. Louis, detailed the next steps needed to build on the results from a study (abstract #1450) of blinatumomab (Blincyto) presented at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.

Transcription:

I think the result of [the abstract #1450 are] promising. That means we have to do more investigation. Still, 4 patients obviously relapsed later on, but we have ideas in terms of designing the next larger trial using T-cell engagers as consolidation after BEAM [carmustine, etoposide, cytarabine, and melphalan] autologous stem cell transplantation. I think this pilot trial shows that this is a promising strategy. We have to refine it and do it in a larger study—hopefully in a randomized fashion—to show that [by] using such a strategy, we can cure more patients. And hopefully more patients are going to be in a disease-free survival status later on after BEAM autologous transplant.

Recent Videos
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content